A New Frontier in the Treatment of Epidermal Growth Factor Receptor-mutated Non–Small-Cell Lung Cancer: Amivantamab-vmjw and Chemotherapy

Until recently, chemotherapy had been the standard of care for patients with advanced non-small-cell lung cancer (NSCLC) with classical epidermal growth factor receptor (EGFR) mutations progressing on osimertinib.It also remained as the first-line treatment for patients with advanced NSCLC harbouring EGFR exon 20 insertions.The recent results from the MARIPOSA-2 and PAPILLON phase III clinical trials demonstrate that the addition of amivantamab-vmjw, a bispecific antibody targeting the EGFR and mesenchymal-epithelial transition factor pathways, to chemotherapy offers improved clinical benefits in both settings when compared with chemotherapy alone.